Immix Biopharma IMMX 深 沪
已收盘 10-02 16:00:00 美东时间
9.68
-0.550
-5.38%
华盛通- 最 高10.37
- 今 开10.35
- 成交量 254.82万股
- 最 低 9.48
- 昨 收 10.23
- 总市值 6.93亿
- 52周最高 15.10
- 市盈率 静 --
- 换手率 3.56%
- 52周最低 2.31
- 委 比 -98.72%
- 总股本 7153.93万
- 历史最高 15.10
- 量 比 1.01
- 振 幅 8.70%
- 历史最低 0.68
- 每 手 1
- 风险率 3.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immix Biopharma Prices $125 Million Equity Offering
An announcement from Immix Biopharma ( ($IMMX) ) is now available. On September...
10-01 05:29
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30
Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $21 to $30.
09-30 00:54
Immix rises after new mid-stage trial data for AL amyloidosis therapy
Despite announcing a $125M stock offering, Immix Biopharma (IMMX) traded higher in the premarket on Tuesday after a positive data update from a mid-stage trial for its lead asset, NXC-201, in AL amylo...
09-29 21:13
Immix Biopharma prices $125M stock offering
Immix Biopharma (IMMX) said it priced an underwritten registered offering of 11.36M shares of common stock at $11 per share, with gross proceeds expected to reach $125M . The offering is expected to c...
09-29 19:33
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
Immix Biopharma announced interim results of NEXICART-2 trial showing NXC-201 achieved 89% complete response (CR) rate in 45 AL Amyloidosis patients. All 25 new patients are in CR or MRD-negative, with MRD-negative patients reaching CR within a year. No relapses, neurotoxicity, or enterocolitis observed. Potential CR rate could rise to 98% with pending patients. Final readout and BLA submission planned for mid-2027. NXC-201 is a BCMA-targeted CAR...
09-29 11:00
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $15 to $26.
09-15 21:41
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $20 to $25.
08-10 20:10
